Skip to main content

Advertisement

SpringerLink
Log in

Reaching the Unreached: Treatment as Prevention as a Workable Strategy to Mitigate HIV and Its Consequences in High-Risk Groups

  • Treatment as Prevention (RM Granich, Section Editor)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

While there have been significant advances in curbing the HIV disease epidemic worldwide, there continues to be significant number of incident cases with 2.3 million new infections in the year 2012 alone. Treatment as prevention (TasP), which involves the use of antiretroviral drugs to decrease the likelihood of HIV illness, death and transmission from infected individuals to their noninfected sexual and /or drug paraphernalia-sharing injecting partners, must be incorporated into any HIV prevention strategy that is going to be successful on a large scale. Especially in resource-limited settings, the focus of the prevention approach should be on high-risk groups who contribute disproportionately to community HIV transmission, including people who inject drugs (PWID), men who have sex with men (MSM) and sex workers. Innovative strategies including integrated care services adapted to different patient care settings have to and can be employed to reach these at-risk populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. HIV surveillance—United States, 1981–2008. MMWR Morb Mortal Wkly Rep. 2011;60(21):689–93.

  2. Global report: Unaids report on the global aids epidemic 2013. Press Release; 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf.

  3. World fertility data 2012. 2013. http://www.un.org/esa/population/publications/WFD2012/MainFrame.html.

  4. Farnham PG, Holtgrave DR, Sansom SL, Hall HI. Medical costs averted by HIV prevention efforts in the United States, 1991–2006. J Acquir Immune Defic Syndr. 2010;54(5):565–7.

    Article  PubMed  Google Scholar 

  5. Lansky A, Brooks JT, DiNenno E, Heffelfinger J, Hall HI, Mermin J. Epidemiology of HIV in the United States. J Acquir Immune Defic Syndr. 2010;55 Suppl 2:S64–8.

    Article  PubMed  Google Scholar 

  6. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA J Am Med Assoc. 2008;300(5):520–9.

    Article  CAS  Google Scholar 

  7. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209–16.

    Article  PubMed  Google Scholar 

  8. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–99.

  10. Getting to zero: HIV in eastern and Southern Africa. Press Release; 2013. http://www.unicef.org/esaro/Getting-to-Zero-2013.pdf.

  11. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric aids clinical trials group protocol 076 study group. N Engl J Med. 1994;331(18):1173–80.

    Article  CAS  PubMed  Google Scholar 

  12. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. van Asten L, Prins M. Infection with concurrent multiple hepatitis c virus genotypes is associated with faster HIV disease progression. AIDS. 2004;18(17):2319–24.

    Article  PubMed  Google Scholar 

  14. McNairy ML, Cohen M, El-Sadr WM. Antiretroviral therapy for prevention is a combination strategy. Curr HIV/AIDS Rep. 2013;10(2):152–8.

    Article  PubMed  Google Scholar 

  15. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS. 2010;24(5):729–35.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Hayes R, Sabapathy K, Fidler S. Universal testing and treatment as an HIV prevention strategy: research questions and methods. Curr HIV Res. 2011;9(6):429–45.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Bruce RD. Is it time for treatment as prevention among people who inject drugs? J Acquir Immune Defic Syndr. 2013;63(5):545–7.

    Article  PubMed  Google Scholar 

  18. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. Hiv prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014–28.

    Article  PubMed  Google Scholar 

  19. Baral SD, Stromdahl S, Beyrer C. The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Curr Opin HIV AIDS. 2012;7(6):563–8.

    Article  PubMed  Google Scholar 

  20. Stimson GV, Fitch C, DesJarlais D, Poznyak V, Perlis T, Oppenheimer E, et al. Rapid assessment and response studies of injection drug use: knowledge gain, capacity building, and intervention development in a multisite study. Am J Public Health. 2006;96(2):288–95.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Huang YF, Yang JY, Nelson KE, Kuo HS, Lew-Ting CY, Yang CH, et al. Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts. PLoS Med. 2014;11(4):e1001625.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Kato M, Granich R, Bui DD, Tran HV, Nadol P, Jacka D, et al. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. J Acquir Immune Defic Syndr. 2013;63(5):e142–9.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Parsons D, Burrows D, Bolotbaeva A. Advocating for opioid substitution therapy in central Asia: much still to be done. Int J Drug Policy. 2014.

  24. Rhodes SD, Hergenrather KC, Vissman AT, Stowers J, Davis AB, Hannah A, et al. Boys must be men, and men must have sex with women: a qualitative cbpr study to explore sexual risk among African American, Latino, and white gay men and MSM. Am J Men’s Health. 2011;5(2):140–51.

    Article  Google Scholar 

  25. Maulsby C, Millett G, Lindsey K, Kelley R, Johnson K, Montoya D, et al. A systematic review of HIV interventions for black men who have sex with men (MSM). BMC Public Health. 2013;13(625).

  26. Phillips 2nd G, Wohl A, Xavier J, Jones K, Hidalgo J. Epidemiologic data on young men of color who have sex with men. AIDS Patient Care STDs. 2011;25 Suppl 1:S3–8.

    Article  PubMed  Google Scholar 

  27. HIV prevention among Black/African American gay, bisexual, and other men who have sex with men: highlights of activities of the centers for disease control and prevention. Atlanta; 2013. http://www.cdc.gov/hiv/risk/racialethnic/aa/brief/index.html.

  28. Scheer S, Kellogg T, Klausner JD, Schwarcz S, Colfax G, Bernstein K, et al. HIV is hyperendemic among men who have sex with men in San Francisco: 10-year trends in HIV incidence, HIV prevalence, sexually transmitted infections and sexual risk behaviour. Sex Transm Infect. 2008;84(6):493–8.

    Article  CAS  PubMed  Google Scholar 

  29. Cunha CB, De Boni RB, Guimaraes MR, Yanavich C, Veloso VG, Moreira RI, et al. Unprotected sex among men who have sex with men living with HIV in Brazil: a cross-sectional study in Rio de Janeiro. BMC Public Health. 2014;14(379).

  30. Crepaz N, Marks G, Liau A, Mullins MM, Aupont LW, Marshall KJ, et al. Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis. AIDS. 2009;23(13):1617–29.

    Article  PubMed  Google Scholar 

  31. Muessig KE, Pike EC, Fowler B, LeGrand S, Parsons JT, Bull SS, et al. Putting prevention in their pockets: developing mobile phone-based HIV interventions for black men who have sex with men. AIDS Patient Care STDs. 2013;27(4):211–22.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Sullivan PS, Grey JA, Simon Rosser BR. Emerging technologies for HIV prevention for MSM: what we have learned, and ways forward. J Acquir Immune Defic Syndr. 2013;63 Suppl 1:S102–7.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):Cd004145.

  34. Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr. 2014;66(3):288–93.

    Article  CAS  PubMed  Google Scholar 

  35. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.

    Article  PubMed  Google Scholar 

  36. Gap report. Press Release; 2014. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf.

  37. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. Dependent areas—2011. Press Release; 2013.

  38. Paltiel AD, Weinstein MC, Kimmel AD, Seage 3rd GR, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95.

    Article  CAS  PubMed  Google Scholar 

  39. Delamothe T. Wanted: guidelines that doctors will follow. BMJ. 1993;307(6898):218.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, et al. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014;9(1):e84317.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013;10(8):e1001496.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Bruce RD, Lambdin B, Chang O, Masao F, Mbwambo J, Mteza I, et al. Lessons from tanzania on the integration of HIV and tuberculosis treatments into methadone assisted treatment. Int J Drug Policy. 2014;25(1):22–5.

  43. Kaai S, Bullock S, Burchell AN, Major C. Factors that affect HIV testing and counseling services among heterosexuals in Canada and the United Kingdom: an integrated review. Patient Educ Couns. 2012;88(1):4–15.

    Article  PubMed  Google Scholar 

  44. Angotti N, Bula A, Gaydosh L, Kimchi EZ, Thornton RL, Yeatman SE. Increasing the acceptability of HIV counseling and testing with three c’s: convenience, confidentiality and credibility. Soc Sci Med. 2009;68(12):2263–70.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of art associated with decline in risk of HIV acquisition in rural Kwazulu-natal, South Africa. Science. 2013;339(6122):966–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–11): a national observational cohort study. Lancet. 2013;382(9899):1195–203.

    Article  PubMed  Google Scholar 

  49. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–6.

    Article  PubMed  Google Scholar 

  50. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.

    Article  PubMed  Google Scholar 

  51. Williams ML, McCurdy SA, Bowen AM, Kilonzo GP, Atkinson JS, Ross MW, et al. HIV seroprevalence in a sample of Tanzanian intravenous drug users. AIDS Educ Prev. 2009;21(5):474–83.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014.

  53. Services DoHaH. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In.

  54. Choi KH, Lui H, Guo Y, Han L, Mandel JS. Lack of HIV testing and awareness of HIV infection among men who have sex with men, Beijing, China. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 2006;18(1):33–43.

    Article  Google Scholar 

  55. Ainsworth M, Teokul W. Breaking the silence: setting realistic priorities for aids control in less-developed countries. Lancet. 2000;356(9223):55–60.

    Article  CAS  PubMed  Google Scholar 

  56. Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy. 2010;21(2):122–4.

    Article  PubMed Central  PubMed  Google Scholar 

  57. USAID Ukraine: report on integrated treatment for HIV-infected opioid dependent persons: Ukraine. Press Release; 2010.

  58. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(6):793–800.

    Article  Google Scholar 

  59. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding art for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050. PLoS One. 2012;7(2):e30216.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Kahn JG, Marseille EA, Bennett R, Williams BG, Granich R. Cost-effectiveness of antiretroviral therapy for prevention. Curr HIV Res. 2011;9(6):405–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369(18):1715–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  62. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Schwartz A, et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS. 2006;20(17):2207–15.

    Article  PubMed  Google Scholar 

  63. Sarang A, Rhodes T, Sheon N. Systemic barriers accessing HIV treatment among people who inject drugs in Russia: a qualitative study. Health Policy Plan. 2012.

  64. Wilson IB, Landon BE, Ding L, Zaslavsky AM, Shapiro MF, Bozzette SA, et al. A national study of the relationship of care site HIV specialization to early adoption of highly active antiretroviral therapy. Med Care. 2005;43(1):12–20.

    PubMed  Google Scholar 

  65. Wilson IB, Landon BE, Hirschhorn LR, McInnes K, Ding L, Marsden PV, et al. Quality of HIV care provided by nurse practitioners, physician assistants, and physicians. Ann Intern Med. 2005;143(10):729–36.

    Article  PubMed  Google Scholar 

  66. Samb B, Celletti F, Holloway J, Van Damme W, De Cock KM, Dybul M. Rapid expansion of the health workforce in response to the HIV epidemic. N Engl J Med. 2007;357(24):2510–4.

    Article  CAS  PubMed  Google Scholar 

  67. Katz MH. Human immunodeficiency virus is (once again) a primary care disease. Arch Intern Med. 2011;171(8):719–20.

    Article  PubMed  Google Scholar 

  68. Kranzer K, Govindasamy D, van Schaik N, Thebus E, Davies N, Zimmermann M, et al. Incentivized recruitment of a population sample to a mobile HIV testing service increases the yield of newly diagnosed cases, including those in need of antiretroviral therapy. HIV Med. 2012;13(2):132–7.

    Article  CAS  PubMed  Google Scholar 

  69. van Schaik N, Kranzer K, Wood R, Bekker LG. Earlier HIV diagnosis—are mobile services the answer? S Afr Med j = Suid-Afrikaanse tydskrif vir geneeskunde. 2010;100(10):671–4.

    Google Scholar 

  70. Ahmed S, Delaney K, Villalba-Diebold P, Aliyu G, Constantine N, Ememabelem M, et al. HIV counseling and testing and access-to-care needs of populations most-at-risk for HIV in Nigeria. AIDS Care. 2013;25(1):85–94.

    Article  PubMed  Google Scholar 

  71. Wang H, Zhou J, Huang L, Li X, Fennie KP, Williams AB. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China. J Clin Nurs. 2010;19(3–4):380–8.

    Article  CAS  PubMed  Google Scholar 

  72. Gardner LI, Marks G, Craw JA, Wilson TE, Drainoni ML, Moore RD, et al. A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55(8):1124–34.

    Article  Google Scholar 

  73. Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012;3, Cd009756.

    PubMed  Google Scholar 

  74. Gaur AH, Belzer M, Britto P, Garvie PA, Hu C, Graham B, et al. Directly observed therapy (dot) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retrovir. 2010;26(9):947–53.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Flanigan TP, Taylor LE, Mitty JA. Use of community-based, directly observed therapy for HIV infection: lessons learned for treatment of hepatitis c virus infection. Clin Infect Dis. 2005;40 Suppl 5:S346–8.

    Article  PubMed  Google Scholar 

  76. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011;113(2–3):192–9.

    Article  PubMed Central  PubMed  Google Scholar 

  77. Cunningham CO, Sohler NL, Wong MD, Relf M, Cunningham WE, Drainoni ML, et al. Utilization of health care services in hard-to-reach marginalized HIV-infected individuals. AIDS Patient Care STDs. 2007;21(3):177–86.

    Article  PubMed  Google Scholar 

  78. Wolitski RJ, Kidder DP, Pals SL, Royal S, Aidala A, Stall R, et al. Randomized trial of the effects of housing assistance on the health and risk behaviors of homeless and unstably housed people living with HIV. AIDS Behav. 2010;14(3):493–503.

    Article  PubMed  Google Scholar 

  79. Wood E, Hogg RS, Yip B, Dong WW, Wynhoven B, Mo T, et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS. 2005;19(11):1189–95.

    Article  PubMed  Google Scholar 

  80. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56 Suppl 1:S22–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Dolgin E. Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med. 2014;20(4):323–4.

    Article  CAS  PubMed  Google Scholar 

  82. Cohen J. Virology. A bid to thwart HIV with shot of long-lasting drug. Science. 2014;343(6175):1067.

    Article  CAS  PubMed  Google Scholar 

  83. Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, et al. Tenofovir alafenamide vs. Tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Onyema Ogbuagu and R. Douglas Bruce declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Yale University AIDS Program, New Haven, CT, USA

    Onyema Ogbuagu & R. Douglas Bruce

  2. Cornell Scott-Hill Health Center, Yale University, 428 Columbus Avenue, New Haven, CT, 06519, USA

    R. Douglas Bruce

Authors
  1. Onyema Ogbuagu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Douglas Bruce
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Douglas Bruce.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogbuagu, O., Bruce, R.D. Reaching the Unreached: Treatment as Prevention as a Workable Strategy to Mitigate HIV and Its Consequences in High-Risk Groups. Curr HIV/AIDS Rep 11, 505–512 (2014). https://doi.org/10.1007/s11904-014-0238-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-014-0238-4

Keywords

Search

Navigation